Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Grammatico

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Oncology|May 14, 2023
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma NetworkElisabetta Antonioli, Sofia Pilerci, Irene Attucci, et al.
American Journal of Hematology|September 29, 2011
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion geneLoredana Elia, Sara Grammatico, Francesca Paoloni, et al.
Cardiovascular & Hematological Agents in Medicinal Chemistry|April 7, 2016
Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological MalignancyGregorio A Brunetti, Giovanna Palumbo, Giacomo S Morano, et al.
Haematologica|January 13, 2010
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adultsPaolo Gorello, Roberta La Starza, Emanuela Varasano, et al.
Cancer|July 13, 2012
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic formAngela Rago, Sara Grammatico, Tommaso Za, et al.
Cancer|December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisManuela Gambella, Paola Omedé, Stefano Spada, et al.
British Journal of Haematology|April 21, 2018
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implicationsSabina Chiaretti, Monica Messina, Sara Grammatico, et al.
Critical Reviews in Oncology/Hematology|September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysisSara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Oncology|May 14, 2023
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma NetworkElisabetta Antonioli, Sofia Pilerci, Irene Attucci, et al.
American Journal of Hematology|September 29, 2011
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion geneLoredana Elia, Sara Grammatico, Francesca Paoloni, et al.
Cardiovascular & Hematological Agents in Medicinal Chemistry|April 7, 2016
Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological MalignancyGregorio A Brunetti, Giovanna Palumbo, Giacomo S Morano, et al.
Haematologica|January 13, 2010
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adultsPaolo Gorello, Roberta La Starza, Emanuela Varasano, et al.
Cancer|July 13, 2012
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic formAngela Rago, Sara Grammatico, Tommaso Za, et al.
Cancer|December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisManuela Gambella, Paola Omedé, Stefano Spada, et al.
British Journal of Haematology|April 21, 2018
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implicationsSabina Chiaretti, Monica Messina, Sara Grammatico, et al.
Critical Reviews in Oncology/Hematology|September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysisSara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.
Pageof 2